PF-00489791

DRUG5 trials

Sponsors

Pfizer

Conditions

Diabetic NephropathiesHealthy VolunteersHypertensionHypertension, PulmonaryPeripheral Vascular DiseaseRaynaud's Disease

Phase 1

A Study to Estimate the Effect of CYP3A4 Inhibitors (Itraconazole, Diltiazem or Verapamil) on the Pharmacokinetics of Single Dose PF- 00489791 in Healthy Volunteers

CompletedNCT02319148

PfizerHealthy Volunteers

Start: 2014-07-31End: 2014-10-31Updated: 2016-09-16

Phase 2

A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure

CompletedNCT00422461

PfizerHypertension

Start: 2007-02-27End: 2008-01-28Updated: 2021-10-11

A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension

TerminatedNCT00853112

PfizerHypertension, Pulmonary

Start: 2009-04-30End: 2010-07-31Updated: 2017-10-24

PF-00489791 For The Treatment Of Raynaud's

CompletedNCT01090492

PfizerPeripheral Vascular Disease, Raynaud's Disease

Start: 2010-08-04End: 2011-05-31Updated: 2018-05-16

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

CompletedNCT01200394

PfizerDiabetic Nephropathies

Start: 2010-12-31End: 2013-08-31Updated: 2019-03-12